title: Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
abstract: OBJECTIVE
  To evaluate toxicity, response and progression-free survival of single nedaplatin chemotherapy in women with platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancer.
  
  
  METHODS
  Seventeen patients with platinum/taxane-resistant/refractory epithelial ovarian, fallopian tube or primary peritoneal cancer who were treated with a single nedaplatin regimen at 90 mg/m(2) administration on day 1 of a 28-day cycle in our institution between 2005 and 2007 were retrospectively investigated.
  
  
  RESULTS
  Ten of 17 patients (59%) had measurable disease. Seven patients were evaluated according to cancer antigen (CA) 125 levels. The overall response was 24% (complete response, 2 patients; partial response, 2 patients). Two of these 4 patients had measurable disease. Stable disease and progressive disease was noted in 6 (35%) and 7 (41%) patients. Median progression-free survival was 8 months (range 3-11) in patients who responded to therapy and 4 months (range 2-6) in patients with stable disease. Mean platinum-free interval due to treatment without using platinum analogues after developing platinum-resistant/refractory disease was 11 months (range 8-12) in patients who responded to nedaplatin regimen and 3 months (range 1-11) in patients who did not (P < 0.01), whereas mean treatment-free interval was 3 months (range 1-5) in responders and 1 month (range 1-3) in non-responders, which did not show a significant difference. Grade 4 hematological toxicity was observed in 2 of 17 patients (12%). No grade 3 or 4 non-hematological toxicity occurred. All toxicities were managed on an outpatient basis.
  
  
  CONCLUSIONS
  Single nedaplatin treatment for platinum/taxane-resistant/refractory ovarian, tubal and peritoneal cancer patients is the candidate of salvage chemotherapy with comparable effectiveness and less toxicity to other approved regimens.
authors.affiliation: Department of Gynaecologic Oncology, Saitama Medical University International Medical Centre Comprehensive Cancer Centre, Hidaka, Japan. tgoto@ndmc.ac.jp
authors.forename: Tomoko
authors.initials: T
authors.lastname: Goto
authors.forename: Masashi
authors.initials: M
authors.lastname: Takano
authors.forename: Rie
authors.initials: R
authors.lastname: Ohishi
authors.forename: Norihiro
authors.initials: N
authors.lastname: Iwasa
authors.forename: Motohiro
authors.initials: M
authors.lastname: Shimizu
authors.forename: Kosei
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Shoji
authors.initials: S
authors.lastname: Nagao
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fujiwara
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin